RACGAP1 was initially identified in testis and male germ cells and has been demonstrated to be a key regulator in various malignancies, such as colorectal cancer (Zhou et al., 2018), ovarian cancer (Wang et al., 2018), meningioma (Ke et al., 2013), uterine cancer (Ebinger et al., 2016), and breast cancer (Ren et al., 2021). Here, RACGAP1 is linked to ovarian carcinoma.